{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:58:43Z","timestamp":1758632323645},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T00:00:00Z","timestamp":1233619200000},"content-version":"vor","delay-in-days":4326,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[1997,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background<\/jats:italic>: Amiodarone hydrochloride has been in use for two decades for the control of ventricular and supraventricular arrhythmias. Established and emerging evidence indicates that amiodarone has an antiarrhythmic efficacy superior to that of most other drugs.<\/jats:p><jats:p><jats:italic>Hypothesis<\/jats:italic>: The study was undertaken to evaluate the efficacy and acceptability of low\u2010dose amiodarone therapy in the long\u2010term management of supraventricular and ventricular tachyarrhythmias.<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>: A total of 124 patients with symptomatic drug\u2010refractory or life\u2010threatening arrhythmias managed with low\u2010dose oral amiodarone therapy over a 10\u2010year period was analyzed retrospectively. Of these, 45 patients (36%) had ventricular arrhythmias, 52 (42%) had atrial arrhythmias, and 27 (22%) had atrioventricular reentry tachycardia. Loading doses of amiodarone 600 mg daily for 1 week were administered for supraventricular arrhythmias and 600\u20131200 mg daily for 2 weeks for ventricular arrhythmias. Maintenance daily doses were 194 \u00b1 48 and 206 \u00b1 55 mg, respectively. Mean treatment duration was 32 \u00b1 28 months, with 326.3 patient years of therapy.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>: Of 39 patients with sustained ventricular tachyarrhythmias, the actuarial incidence of satisfactory arrhythmia control (absence of sudden cardiac death or nonfatal arrhythmia recurrence) was 78% at 1 year and 71 % at 2 years. Satisfactory control of supraventricular arrhythmias (mean ventricular rate &lt; 100\/min with significant symptomatic improvement for sustained atrial arrhythmias and &lt; 1 attack per year for paroxysmal atrial or atrioventricular arrhythmias) was achieved in 73, 65, and 62% of patients at 1, 2, and 3 years, respectively. The cumulative incidence of amiodarone\u2010related adverse effects was 5.8 per 100 patient years, with drug withdrawal required in 12 patients (9.7%). Fifteen patients had thyroid dysfunction, 2 had hepatic toxicity, and 1 developed nonfatal pulmonary fibrosis. Overall, the incidence of successful use of amiodarone (satisfactory arrhythmia control and freedom from side effects) was 67, 59, and 53% at 1, 2, and 3 years, respectively.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>: The results of this study suggest that the efficacy of low\u2010dose amiodarone therapy in the management of serious ventricular and supraventricular arrhythmias would be similar to those achieved with higher doses, but with a much more acceptable side effect profile.<\/jats:p>","DOI":"10.1002\/clc.4960200414","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T00:23:38Z","timestamp":1233707018000},"page":"372-377","source":"Crossref","is-referenced-by-count":28,"title":["Long\u2010term low\u2010dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: Efficacy and safety"],"prefix":"10.1002","volume":"20","author":[{"given":"K\u00e4Thy L.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yau\u2010Ting","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,3]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(74)90200-8"},{"key":"e_1_2_1_3_2","first-page":"455","article-title":"Drug therapy: Amiodarone","volume":"316","author":"Mason JW","year":"1988","journal-title":"N Engl J Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(83)80338-6"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.68.1.88"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90206-7"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(89)90525-1"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.67.1.45"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6386.175"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90969-O"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.suppl_H.14"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.93.1.54"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(93)90063-F"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90967-H"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1001\/jama.1992.03480240051033","article-title":"Low\u2010dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter","volume":"267","author":"Gosselink ATM","year":"1992","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1995.tb06733.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90673-Z"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90973-G"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90974-H"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.2.309"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90357-S"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91895-3"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960200414","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.4960200414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T06:45:41Z","timestamp":1698475541000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960200414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["10.1002\/clc.4960200414"],"URL":"https:\/\/doi.org\/10.1002\/clc.4960200414","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,4]]}}}